When these glioma patients (grades 2–4: n = 667) were divided into two groups by ACTA2 expression, those with high ACTA2 expression (n = 285) had a significantly worse prognosis than those with low expression (n = 382) (Figure S3A, p < 0.01). Here, ACTA2 is linked to central nervous system cancer.